Literature DB >> 2032235

Overexpression and mutation of p53 in epithelial ovarian cancer.

J R Marks1, A M Davidoff, B J Kerns, P A Humphrey, J C Pence, R K Dodge, D L Clarke-Pearson, J D Iglehart, R C Bast, A Berchuck.   

Abstract

We examined p53 expression in 107 epithelial ovarian cancers with immunohistochemical techniques using monoclonal antibody PAb1801. High level expression of nuclear p53 protein was detected in the malignant epithelium in 54 (50%) of these cancers. Expression of p53 protein was undetectable in 13 benign gynecological tissues. p53 mRNA from three cancers that overexpressed the protein were sequenced and point mutations which altered the coding sequence of the highly conserved region of the gene were found in each case. Three cancers with undetectable protein levels also were sequenced and were found to be wild-type through the same region of the gene. As in other cancers, overexpression of the p53 protein in ovarian cancer appears to correlate closely with the presence of mutation in the p53 gene. p53 overexpression did not correlate with stage, histological grade, or the ability to perform optimal cytoreductive surgery. A significant correlation (P = 0.04) was observed between p53 overexpression and aneuploidy in advanced stage (III/IV) disease. There was no significant relationship between overall survival and p53 expression. Since mutation and overexpression of p53 are common in epithelial ovarian cancers, further studies are warranted to clarify the role of p53 in ovarian tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2032235

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  93 in total

1.  Somatic mutations of the PPP2R1B candidate tumor suppressor gene at chromosome 11q23 are infrequent in ovarian carcinomas.

Authors:  R Wu; D C Connolly; X Ren; E R Fearon; K R Cho
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

2.  Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome.

Authors:  A Reles; A Schmider; M F Press; I Schönborn; W Friedmann; S Huber-Schumacher; T Strohmeyer; W Lichtenegger
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  Changes of serum p53 antibodies and clinical significance of radiotherapy for esophageal squamous cell carcinoma.

Authors:  Hong-Yi Cai; Xiao-Hu Wang; Ying Tian; Li-Ying Gao; Li-Juan Zhang; Zhi-Yan Zhang
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

4.  P53 mutation in acute T cell lymphoblastic leukemia is of somatic origin and is stable during establishment of T cell acute lymphoblastic leukemia cell lines.

Authors:  J Yeargin; J Cheng; A L Yu; R Gjerset; M Bogart; M Haas
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

5.  Prognostic significance of immunohistochemical expression of p53 gene product in operable breast cancer.

Authors:  Hong Suk Song; Young Rok Do; Sun Hee Kang; Ki Yong Jeong; Yu Sa Kim
Journal:  Cancer Res Treat       Date:  2006-12-31       Impact factor: 4.679

6.  Phenotypic variations and differential migration of NIH:OVCAR-3 ovarian carcinoma cells isolated from athymic mice.

Authors:  A L Veatch; L F Carson; S Ramakrishnan
Journal:  Clin Exp Metastasis       Date:  1995-05       Impact factor: 5.150

7.  Synchronous colon carcinomas: molecular-genetic evidence for multicentricity.

Authors:  R J Koness; T C King; S Schechter; S F McLean; C Lodowsky; H J Wanebo
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

8.  Expression signatures of TP53 mutations in serous ovarian cancers.

Authors:  Marcus Q Bernardini; Tsukasa Baba; Paula S Lee; Jason C Barnett; Gregory P Sfakianos; Angeles Alvarez Secord; Susan K Murphy; Edwin Iversen; Jeffrey R Marks; Andrew Berchuck
Journal:  BMC Cancer       Date:  2010-05-26       Impact factor: 4.430

9.  Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization.

Authors:  G Sauter; G Deng; H Moch; R Kerschmann; K Matsumura; S De Vries; T George; J Fuentes; P Carroll; M J Mihatsch
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

10.  Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases.

Authors:  P Laurent-Puig; R Lubin; S Semhoun-Ducloux; G Pelletier; C Fourre; M Ducreux; M J Briantais; C Buffet; T Soussi
Journal:  Gut       Date:  1995-03       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.